Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Dow
Baxter
Mallinckrodt
Colorcon

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Tegafur-uracil


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Tegafur-uracil?

Tegafur-uracil is an investigational drug.

There have been 89 clinical trials for Tegafur-uracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, National Cancer Institute (NCI), and Taiho Oncology, Inc.

There are six hundred and sixty-five US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Tegafur-uracil
TitleSponsorPhase
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction AdenocarcinomaSun Yat-sen UniversityPhase 2
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2/Phase 3
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerShengjing HospitalPhase 2

See all Tegafur-uracil clinical trials

Clinical Trial Summary for Tegafur-uracil

Top disease conditions for Tegafur-uracil
Top clinical trial sponsors for Tegafur-uracil

See all Tegafur-uracil clinical trials

US Patents for Tegafur-uracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur-uracil ⤷  Try it Free Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC) ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Antibody formulations GENENTECH, INC. (South San Francisco, CA) ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Molecular constructs with targeting and effector moieties ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Glutaminase inhibitors and method of use Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Methods and compositions for inhibition of Ras ARAXES PHARMA LLC (San Diego, CA) ⤷  Try it Free
Tegafur-uracil ⤷  Try it Free Methods of treating lung cancer FIVE PRIME THERAPEUTICS, INC. (South San Francisco, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur-uracil

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur-uracil World Intellectual Property Organization (WIPO) WO2015148714 2034-03-25 ⤷  Try it Free
Tegafur-uracil Australia AU2015231053 2034-03-21 ⤷  Try it Free
Tegafur-uracil Brazil BR112016021620 2034-03-21 ⤷  Try it Free
Tegafur-uracil Canada CA2943339 2034-03-21 ⤷  Try it Free
Tegafur-uracil China CN106231900 2034-03-21 ⤷  Try it Free
Tegafur-uracil Eurasian Patent Organization EA201691896 2034-03-21 ⤷  Try it Free
Tegafur-uracil European Patent Office EP3119199 2034-03-21 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Dow
Baxter
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.